Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery

DISEASE CHARACTERISTICS: * Histologically confirmed hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC) * Peripheral, cholangiolar, or cholangiocellular types * Mixed HCC/ICC disease allowed * Unresectable disease * Less than 70% liver involvement * Radiographically bidimensionally measurable disease, defined as lesion ≥ 2 cm in the greatest diameter * May have failed prior systemic chemotherapy or ablative therapy * No radiographic evidence of esophageal varices * No history of variceal hemorrhage * No occlusion of the main portal vein or the right and left portal branches * No clinical ascites * Patients ineligible for first-line MSKCC protocols for HCC are eligible for this study provided there is no clinical or radiographic evidence of extrahepatic disease * No metastatic disease, including CNS metastases PATIENT CHARACTERISTICS: * Life expectancy ≥ 12 weeks * Karnofsky performance status 60-100% * Considered a candidate for general anesthesia and hepatic artery pump placement * Platelet count \> 100,000/mm³ * Albumin \> 2.5 g/dL * Bilirubin \< 1.8 mg/dL * WBC \> 3,500/mm³ * PTT \< 1.5 times upper limit of normal * INR \< 1.5 OR in-range INR (usually 2.0-3.0) for patients on a stable dose of therapeutic warfarin * Urine protein \< 1+ by dipstick or urine analysis OR urine protein:creatinine ratio \< 1.0 * If proteinuria ≥ 2+ at baseline, patient must have \< 1 g protein/24-hour collection * No concurrent disease or illness that would pre…